Popular menopause prescriptions such as Estradiol, Dotti, Premarin and Veozah will be available for cheaper using a GoodRx coupon.
menopause sign © creative soul - stock.adobe.com
GoodRx announced today the availability of new menopause therapies by Pfizer, as well as a menopause drug savings guide for patients, according to a news release. Eligible patients with a prescription will now be able to find low-cost menopause therapies ranging in price from $99 to $249 at more than 70,000 pharmacies through GoodRx. Prices vary by pharmacy chain and geographic location.
Research from GoodRx shows that the cost of menopause therapies has increased by 58% since 2014. Although women spend an average of $14.33 out of pocket for their menopause drugs, drugs with poorer coverage like Activella, force patients to pay over $100 out of pocket per prescription. With a GoodRx coupon, the cheapest generic Activella in the Pittsburgh area is available for $47.72 at CVS, according to the GoodRx website.
Another study by Elektra Health says that women spend 45% more on healthcare after their menopause diagnosis when compared to before their diagnosis.
“Menopause is a natural phase of a woman’s life that deserves attention and care, not something to be ignored or stigmatized,” Lisa Larkin, immediate past president of The Menopause Society said in the news release. “Efforts like this one are exactly what’s needed to improve health outcomes for women everywhere.”
Menopause not only impacts women physically through symptoms such as hot flashes, but mentally as well by causing depression, anxiety and brain fog.
High menopause medication prices may also be a result of the “pink tax,” which refers to the concept that women’s products are more expensive than men’s, the news release explains. For example, 30 tablets of generic Viagra are available for only $6.27 in the Houston area using a GoodRx coupon.
“By reducing the cost barrier and spotlighting the importance of menopausal health, this initiative directly supports women’s health, their ability to enjoy their lives and encourages a broader dialogue about comprehensive care for all stages of a woman’s life,” Larkin continued.
The Growing Popularity of Non-hormonal Menopause Therapy
February 12th 2025Menopausal patients are most interested in learning more about non-hormonal treatments to address their symptoms, according to the results of an international survey led by the Menopause Priority Setting Partnership (MAPS). Monica Christmas, M.D., director of the menopause program at the University of Chicago Medicine and the Center for Women’s Integrated Health, discussed the survey details with Managed Healthcare Executive.
Read More
The Long Term Cost of Major Menopause Misconceptions
February 5th 2025An overview of menopause taboo, the lingering effects of the Women’s Health Initiative study and what employers can do support their menopausal workers, according to Stephanie Faubion, M.D., director of the Mayo Clinic’s Center for Women’s Health and medical director of The Menopause Society.
Read More